Acquiring Assets from Big Pharma: A How-To Guide
Ok, we have to admit. This is not exactly a "how to" guide. In fact, writing such a guide may not be possible. But first, let's dispel the…
Ok, we have to admit. This is not exactly a "how to" guide. In fact, writing such a guide may not be possible. But first, let's dispel the…
Just sign a piece a paper and drive off with a new car. They sure make it sound east, don't they? Yet VW does have a good point.…
Biotech business development has become more sophisticated and more complex. Yet we see companies running processes which are suboptimal. Here is a case in point. We're reviewing several…
It's been difficult to keep up with all the deals this month! We won't review them all here, as that's best done by others. But here are a…
Oramed announced last week that their oral insulin capsule is ready for Phase II trials in the US: Oramed's ORMD-0801 is an orally ingestible insulin capsule indicated for…
In 1941, Let Us Now Praise Famous Men was published. This unusual book is an account of Southern sharecroppers in the Deep South in 1936. It is a difficult…
As we were making our way back home from Chicago (on delayed flights, of course), several things struck us about BIO2013. We've talked about BIO in the past.…
Now that we're back from BIO2013, we have to leave again! We'll be at ExcipientFest 2013 in Baltimore for a few days. We'll be meeting with several Exhibitors,…
Yesterday, North Carolina-based Pozen gave a detailed Investor Update, focused on PA32540, a "Coordinated-Delivery Tablet Containing Enteric-Coated Aspirin and Immediate-RElease Omeprazole." Information on the company's pipeline is available…
Today's issue of FiercePharma covered two interesting FDA decisions (or non- decisions, if you prefer). The first involves the FDA's decision not to approve generic versions of Purdue's Oxycontin:…